NCT00006327
Completed
Phase 3
A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
VaxGen1 site in 1 country2,500 target enrollmentMarch 1999
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- VaxGen
- Enrollment
- 2500
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
Detailed Description
Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV InfectionHIV InfectionsHIV SeronegativityNCT00002441VaxGen5,000
Completed
Phase 1
A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible VaccinesHIV InfectionsNCT00002402VaxGen120
Completed
Phase 1
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205HIV InfectionsNCT02852005National Institute of Allergy and Infectious Diseases (NIAID)27
Completed
Phase 2
Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)AIDSNCT01705223National Center for AIDS/STD Control and Prevention, China CDC150
Completed
Phase 1
Candidate HIV VaccineHIV InfectionsNCT00089531National Institute of Allergy and Infectious Diseases (NIAID)15